Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBEX: Iberdomide + SQ Daratumumab Maintenance in Multiple Myeloma
NCT06107738Phase 2Recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in multiple myeloma (MM), sponsored by Barbara Ann Karmanos Cancer Institute. Started Dec 2023; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06107738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107738.